|Videos|November 23, 2017

Why Are Hospital Mattresses Harder to Disinfect Than Other Surfaces?

Edmond Hooker, MD, DrPH, explains why hospital mattresses are harder to disinfect than other harder surfaces.

Edmond Hooker, MD, DrPH, professor, Health Services Administration at Xavier University, and emergency physician at the University of Cincinnati, explains why hospital mattresses are harder to disinfect than other harder surfaces.

Interview Transcript (modified slightly for readability):

“The key when you’re trying to clean is to disinfect everything to a high level, which we’re not currently doing. Currently, hospital hard surfaces are a lot easier to clean because the chemicals were made for hard surfaces. Unfortunately, the mattress is a soft, porous surface; it was intended to be that to stop all of the bed sores. And so, if you think about a 1970’s car with a vinyl seat, you sat in it, and you sweated, and you stuck to it, and that was miserable. Well, that’s not good for a patient either, and that’s what the mattresses used to be.

Now, we have changed to this breathable fabric. The fabric actually lets moisture get away from the patient; it’s very high-tech. The problem is, it’s porous and soft, and so, all of the chemicals that are being used are the wrong chemicals; they don’t work and they damage the fabric, which causes cracks and crevices that C. difficile and all of the different, nasty bugs can go down and hide in.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.